SUPN

Supernus Pharmaceuticals (SUPN)

About Supernus Pharmaceuticals (SUPN)

Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. It offers Trokendi XR, Oxtellar XR, APOKYN, XADAGO, and MYOBLOC products. The company was founded by Jack A. Khattar on March 30, 2005, and is headquartered in Rockville, MD.

Details

Daily high

$48.84

Daily low

$47.20

Price at open

$47.28

52 Week High

$57.65

52 Week Low

$29.16

Market cap

2.7B

Dividend yield

0.00%

Volume

619,210

Avg. volume

660,976

P/E ratio

-138.73

Supernus Pharmaceuticals News